See more : Renegade Exploration Limited (RNX.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Avista Public Acquisition Corp. II (AHPA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avista Public Acquisition Corp. II, a leading company in the Shell Companies industry within the Financial Services sector.
- Shih Her Technologies Inc. (3551.TWO) Income Statement Analysis – Financial Results
- Borussia Dortmund GmbH & Co. Kommanditgesellschaft auf Aktien (BVB.SW) Income Statement Analysis – Financial Results
- Shenzhen Riland Industry Group Co., Ltd (300154.SZ) Income Statement Analysis – Financial Results
- HELLA GmbH & Co. KGaA (HLE.SW) Income Statement Analysis – Financial Results
- Jetcom Inc. (JTCMF) Income Statement Analysis – Financial Results
Avista Public Acquisition Corp. II (AHPA)
Industry: Shell Companies
Sector: Financial Services
About Avista Public Acquisition Corp. II
Avista Public Acquisition Corp. II does not have significant operations. It intends to acquire assets and businesses through a merger, share exchange, share purchase, reorganization, or similar business combination. The company focuses on pursuing businesses in the healthcare industry. Avista Public Acquisition Corp. II was incorporated in 2021 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 34.16M | 59.08M | 34.75M | 23.27M | 18.32M |
| Cost of Revenue | 0.00 | 16.25M | 14.97M | 0.00 | 0.00 |
| Gross Profit | 34.16M | 42.83M | 19.78M | 23.27M | 18.32M |
| Gross Profit Ratio | 100.00% | 72.49% | 56.92% | 100.00% | 100.00% |
| Research & Development | 56.53M | 48.36M | 39.23M | 24.80M | 13.21M |
| General & Administrative | 33.31M | 24.90M | 16.95M | 10.23M | 8.65M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.31M | 24.90M | 16.95M | 10.23M | 8.65M |
| Other Expenses | 13.75M | 12.46M | 14.18M | 13.87M | 9.49M |
| Operating Expenses | 103.58M | 85.73M | 70.36M | 48.89M | 31.35M |
| Cost & Expenses | 103.58M | 85.73M | 70.36M | 48.89M | 31.35M |
| Interest Income | 5.06M | 587.00K | 7.00K | 5.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 7.00K | 5.00K | 0.00 |
| Depreciation & Amortization | 19.50M | 16.25M | 14.97M | 13.14M | 10.92M |
| EBITDA | -49.73M | -13.01M | -19.38M | -10.59M | -2.11M |
| EBITDA Ratio | -145.57% | -22.02% | -52.06% | -45.50% | -11.52% |
| Operating Income | -69.42M | -26.65M | -35.61M | -25.62M | -13.03M |
| Operating Income Ratio | -203.19% | -45.11% | -102.48% | -110.12% | -71.12% |
| Total Other Income/Expenses | 5.06M | 587.00K | 1.26M | 1.90M | 0.00 |
| Income Before Tax | -64.36M | -26.06M | -34.35M | -23.73M | -13.03M |
| Income Before Tax Ratio | -188.39% | -44.11% | -98.85% | -101.98% | -71.12% |
| Income Tax Expense | -13.74M | -3.73M | -7.31M | -6.17M | 562.00K |
| Net Income | -50.62M | -22.33M | -27.04M | -17.56M | -13.59M |
| Net Income Ratio | -148.16% | -37.80% | -77.82% | -75.46% | -74.18% |
| EPS | -0.51 | -0.26 | -0.33 | -0.15 | -0.12 |
| EPS Diluted | -0.51 | -0.26 | -0.33 | -0.15 | -0.12 |
| Weighted Avg Shares Out | 99.68M | 85.32M | 82.61M | 114.82M | 114.82M |
| Weighted Avg Shares Out (Dil) | 99.68M | 85.32M | 82.61M | 114.82M | 114.82M |
OmniAb Announces Completion of Spin-Off and Business Combination
Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
OmniAb Business Combination Approved by APAC Shareholders
Ligand Announces Record Date and Details for Distribution for OmniAb Spin-Off
Ligand Reports Second Quarter 2022 Financial Results
Source: https://incomestatements.info
Category: Stock Reports